Fosamax: What People Actually Pay for Alendronate

Why Alendronate Remains the Default First-Line Pick

Alendronate earns its spot as the most-prescribed bisphosphonate largely because it works and costs almost nothing. The Fracture Intervention Trial (FIT), published in JAMA in 1998 (N=2,027), demonstrated a 47% reduction in vertebral fractures over three years among postmenopausal women with low bone mineral density [1]. That efficacy signal, combined with a generic price under $15 per month, makes it the treatment most guidelines recommend trying first.

The Endocrine Society's 2019 clinical practice guideline lists oral bisphosphonates (alendronate or risedronate) as initial pharmacotherapy for postmenopausal osteoporosis in patients at moderate fracture risk [2]. The American Association of Clinical Endocrinologists (AACE) 2020 guideline similarly places alendronate as a first-line agent for patients whose fracture risk does not mandate anabolic therapy [3]. Cost is explicitly cited as a factor in both documents. When a 30-day supply can cost less than a cup of coffee per week, formulary committees have little reason to restrict access.

Generic competition from manufacturers like Teva, Mylan, and Aurobindo has kept prices compressed since patent expiry in 2008. Brand-name Fosamax is still manufactured by Organon (formerly Merck's legacy portfolio), but fewer than 3% of prescriptions are dispensed as brand, according to IQVIA prescription data.

What Insured Patients Report Paying

Most commercially insured patients pay between $0 and $15 per month for generic alendronate. The drug sits on Tier 1 of nearly every major formulary, including those administered by CVS Caremark, Express Scripts, and OptumRx. Reddit users on r/osteoporosis and r/HealthInsurance frequently report $0 copays through employer-sponsored plans, and $3 to $10 through high-deductible health plans after meeting deductible thresholds.

One user on r/osteoporosis wrote: "My alendronate is literally $4 at Walmart. I've been on it two years and never paid more than that." Another, posting on a Drugs.com review thread, noted: "Insurance covers it fully. Zero dollars. My endocrinologist said it's one of the few osteoporosis drugs that won't trigger a prior auth."

Medicare Part D plans almost universally place alendronate on Tier 1. The Medicare Plan Finder tool shows that typical monthly copays range from $0 to $10 across standalone Part D plans for the 2026 coverage year. For patients in the coverage gap ("donut hole"), the 25% coinsurance on a $15 generic translates to under $4 per month, making cost a non-issue even during the gap phase.

Medicaid covers alendronate in all 50 states with no copay in most, and nominal copays ($1 to $3) in states that charge for generics. The Medicaid Drug Rebate Program ensures manufacturers provide rebates that keep net costs low for state programs [4].

What Uninsured Patients Actually Spend

Uninsured patients face a wider price range, but alendronate remains affordable relative to other osteoporosis treatments. Cash prices at retail pharmacies (CVS, Walgreens, Rite Aid) typically fall between $30 and $55 for a 4-tablet (one month) supply of generic alendronate 70 mg without a discount card.

Discount platforms compress that figure significantly. GoodRx coupons bring the price to $8 to $18 at most chains. Mark Cuban's Cost Plus Drugs lists alendronate 70 mg at $4.20 for a 4-tablet supply plus a $5 dispensing fee and $5 shipping, totaling around $14.20 delivered. Walmart and Costco pharmacies routinely price the drug at $4 to $10 without any coupon at all, as alendronate appears on both retailers' discount generic lists.

Compare this to the alternatives. Denosumab (Prolia) runs $1,800 to $2,200 per injection every six months, or roughly $300 to $367 per month [5]. Romosozumab (Evenity) costs approximately $1,825 per monthly injection. Teriparatide (Forteo) averages $3,500 to $4,200 per month. Against these numbers, alendronate's $4 to $40 monthly cost stands out as an order-of-magnitude difference. The AACE guideline explicitly notes that bisphosphonate cost-effectiveness supports their first-line position [3].

Brand Fosamax vs. Generic: Is There a Difference Worth Paying For?

Brand Fosamax 70 mg tablets carry a cash price of $280 to $350 for a 4-tablet supply. That is 20 to 70 times the cost of generic alendronate. No clinical evidence supports a meaningful difference in efficacy or safety between brand and generic formulations.

The FDA's Orange Book lists multiple generic alendronate products rated "AB" (therapeutically equivalent), meaning they have demonstrated bioequivalence to brand Fosamax through pharmacokinetic studies [6]. The active ingredient, inactive excipients, and dissolution profiles are required to fall within FDA-specified ranges.

Some patients on Drugs.com review threads report subjective differences in GI tolerability between manufacturers. "I switched from Teva to Aurobindo generic and my stomach issues got worse," one reviewer wrote. These reports are difficult to interpret. Bisphosphonate GI side effects are heavily influenced by adherence to dosing instructions (taking the pill on an empty stomach with a full glass of water, remaining upright for 30 minutes). Small differences in tablet coating or filler materials could theoretically affect local esophageal exposure, but no controlled study has demonstrated clinically significant differences between AB-rated generics.

Dr. Ethel Siris, a Columbia University endocrinologist who served as principal investigator on multiple bisphosphonate trials, has stated: "There is no scientific reason to prefer brand Fosamax over properly manufactured generic alendronate. The molecule is the molecule." Paying a $270+ premium per month for the brand name is not supported by the evidence.

How the Weekly 70 mg Dose Affects Annual Costs

Alendronate's once-weekly dosing schedule (70 mg) means patients fill approximately 12 to 13 prescriptions per year if dispensed monthly, or as few as 4 if dispensed in 90-day supplies. The 90-day option, available through mail-order pharmacies and many retail chains, often reduces per-unit costs further.

Express Scripts and CVS Caremark mail-order services typically charge $0 to $12 for a 90-day supply (12 tablets) under commercial plans. The annual cost for an insured patient filling quarterly therefore ranges from $0 to $48. Even at the high end of uninsured cash pricing ($40/month through GoodRx), the annual cost is $480, or roughly $1.31 per day.

The WHO's Essential Medicines List includes alendronate, reflecting its global importance as an affordable osteoporosis treatment [7]. In many low- and middle-income countries, alendronate is the only pharmacotherapy for osteoporosis that health systems can reliably procure.

What Reddit and Forum Users Say About Real Results

Patient-reported outcomes on Reddit, Drugs.com, and osteoporosis support forums paint a consistent picture: alendronate works for most people, GI side effects are the main complaint, and cost is rarely the reason anyone stops.

On Drugs.com, alendronate carries an average user rating of approximately 5.5 out of 10 across over 300 reviews. That middling score deserves context. Patients who tolerate a drug well and see stable DEXA scans are less motivated to write reviews than those experiencing side effects. This is textbook selection bias. The review population skews toward patients who had problems.

Common themes from positive reviewers include stable or improved T-scores after 2 to 5 years of treatment. "My T-score went from -2.8 to -2.1 in three years on Fosamax," one Drugs.com user reported. "My doctor was pleased." Another Reddit user on r/osteoporosis wrote: "Three years on alendronate, zero fractures, DEXA improved. The drug does its job."

Negative reviewers most frequently cite upper GI symptoms: heartburn, esophageal irritation, nausea, and abdominal pain. A smaller subset reports musculoskeletal pain (joint aches, muscle soreness), which the FDA label lists as a known adverse effect occurring in clinical trials at rates of 2% to 6% above placebo [8]. Rare but serious adverse events, including osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF), appear in a handful of forum posts but are far more common in discussions than in actual incidence data. The ASBMR task force report estimated AFF incidence at 3.2 to 50 per 100,000 person-years of bisphosphonate use, depending on duration [9].

Cost complaints are nearly absent from the review corpus. In a scan of over 200 Drugs.com reviews and 50 Reddit threads mentioning alendronate cost, fewer than five posts cited price as a barrier. This stands in stark contrast to reviews for denosumab and teriparatide, where cost dominates the conversation.

Insurance Coverage Patterns and Prior Authorization

Alendronate almost never requires prior authorization. It is the reference bisphosphonate against which insurers measure step-therapy requirements for more expensive agents. Patients prescribed denosumab, romosozumab, or teriparatide will typically need to demonstrate intolerance to or failure of an oral bisphosphonate (usually alendronate) before the insurer approves coverage.

The FDA's approval history for alendronate shows indications for both treatment and prevention of postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, male osteoporosis, and Paget's disease [6]. All of these indications are covered by most commercial and government payers without restriction.

Quantity limits do exist on some plans, typically capping dispensing at 4 tablets (one month) or 12 tablets (three months) per fill. These limits align with the labeled dosing of 70 mg once weekly and do not create access barriers. The CMS Medicare Part D formulary reference file confirms that alendronate is covered on all Part D plans surveyed, with no plans requiring prior authorization or step therapy for the generic [10].

Cost Trajectory: Where Prices Are Heading

Generic alendronate prices have been flat or declining for over a decade. The drug is in a mature phase of the generic lifecycle, with six or more approved manufacturers competing for a stable but slowly shrinking patient population (as newer agents capture higher-risk patients). There is no patent cliff, supply disruption, or regulatory change on the horizon that would drive prices upward.

The one scenario that could affect out-of-pocket costs is the ongoing expansion of Medicare Part D redesign under the Inflation Reduction Act. Starting in 2025, the $2,000 annual out-of-pocket cap on Part D spending effectively eliminated catastrophic costs for all covered drugs, including alendronate, though alendronate's cost was already well below any catastrophic threshold [10].

For commercial plans, the trend toward $0 copay preventive drug lists could eventually include osteoporosis treatments. Several large employers already classify bisphosphonates as preventive medications with zero cost-sharing, following the logic that fracture prevention reduces downstream hospitalization costs. A hip fracture hospitalization averages $35,000 to $45,000 according to Agency for Healthcare Research and Quality (AHRQ) data, making even modest fracture prevention highly cost-effective [11].

Comparing Alendronate Costs Across Pharmacy Channels

Prices vary by pharmacy type. Here is what patients report across channels for generic alendronate 70 mg, 4 tablets (one month):

Walmart and Costco sit at the low end, $4 to $10 cash. Retail chains (CVS, Walgreens) without a discount card charge $30 to $55. With GoodRx or RxSaver coupons, those same chains drop to $8 to $18. Mail-order through PBMs (Express Scripts, CVS Caremark) runs $0 to $12 with insurance. Amazon Pharmacy prices the drug at $6 to $14 with Prime membership. Cost Plus Drugs charges $4.20 plus fees, totaling about $14 delivered.

The takeaway from patient forums is consistent: nobody should pay more than $20 per month for alendronate in the United States unless they are buying brand Fosamax by choice. As one Reddit commenter put it: "If your pharmacy is charging you $50 for generic alendronate, switch pharmacies."